Shattuck Labs, Inc. (STTK)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 1.0M | 0.00 | 0.00 |
| Operating Income | -13.0M | -10.7M | -13.4M | -15.5M |
| Net Income | -12.5M | -10.1M | -12.6M | -14.8M |
| Diluted EPS | $-0.24 | $-0.14 | $-0.12 | $-0.13 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 652K | 1.7M | 5.7M | 1.0M |
| Operating Income | -103.3M | -92.0M | -80.6M | -51.5M |
| Net Income | -101.9M | -87.3M | -75.4M | -48.8M |
| Diluted EPS | $-2.41 | $-2.05 | $-1.49 | $nan |